• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile.

作者信息

Wu Xiaolong, Schmidt-Wolf Ingo G H

机构信息

Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China.

Department of Integrated Oncology, Center of Integrated Oncology (CIO) Bonn, University Hospital Bonn, Bonn, Germany.

出版信息

Front Immunol. 2022 May 23;13:913123. doi: 10.3389/fimmu.2022.913123. eCollection 2022.

DOI:10.3389/fimmu.2022.913123
PMID:35677035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9170073/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0600/9170073/e4d81e47370a/fimmu-13-913123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0600/9170073/e4d81e47370a/fimmu-13-913123-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0600/9170073/e4d81e47370a/fimmu-13-913123-g001.jpg

相似文献

1
An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile.具有高安全性的同种异体嵌合抗原受体T细胞的替代来源。
Front Immunol. 2022 May 23;13:913123. doi: 10.3389/fimmu.2022.913123. eCollection 2022.
2
Recent advances in cellular therapy for malignant lymphoma.恶性淋巴瘤细胞治疗的最新进展。
Cytotherapy. 2021 Aug;23(8):662-671. doi: 10.1016/j.jcyt.2020.12.007. Epub 2021 Feb 6.
3
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.异体造血细胞移植后复发血液恶性肿瘤患者的细胞因子诱导的杀伤细胞过继免疫治疗。
Biol Blood Marrow Transplant. 2011 Nov;17(11):1679-87. doi: 10.1016/j.bbmt.2011.05.012. Epub 2011 May 25.
4
Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".用嵌合抗原受体武装细胞因子诱导的杀伤细胞：CD28 优于联合 CD28-OX40“超刺激”。
Mol Ther. 2013 Dec;21(12):2268-77. doi: 10.1038/mt.2013.192. Epub 2013 Aug 28.
5
Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.用叶酸受体α（FRα）特异性嵌合抗原受体修饰细胞因子诱导的杀伤细胞可增强其对FRα阳性卵巢癌的抗肿瘤免疫力。
Mol Immunol. 2017 May;85:293-304. doi: 10.1016/j.molimm.2017.03.017. Epub 2017 Mar 27.
6
Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.新型免疫细胞疗法根除高危急性髓系白血病。
Front Immunol. 2021 Aug 3;12:695051. doi: 10.3389/fimmu.2021.695051. eCollection 2021.
7
[Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].[同种异体嵌合抗原受体自然杀伤细胞：自体嵌合抗原受体T细胞的一种有前景的替代方案——现状、自然杀伤细胞来源、局限性与前景]
Bull Cancer. 2021 Oct;108(10S):S81-S91. doi: 10.1016/j.bulcan.2021.06.007.
8
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.嵌合抗原受体工程化细胞因子诱导的杀伤细胞克服前B细胞急性淋巴细胞白血病的治疗耐药性并提高生存率。
Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11.
9
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.基于睡眠美人转座子的 CD19CAR 细胞因子诱导的杀伤细胞治疗急性淋巴细胞白血病的临床前疗效和安全性。
Hum Gene Ther. 2018 May;29(5):602-613. doi: 10.1089/hum.2017.207. Epub 2018 Apr 16.
10
Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.细胞因子诱导的杀伤细胞治疗 EBV 相关恶性淋巴瘤。
Cytotherapy. 2018 Jun;20(6):839-850. doi: 10.1016/j.jcyt.2018.04.005. Epub 2018 May 10.

引用本文的文献

1
Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions.实体瘤的工程化免疫细胞疗法：药理学进展、临床结果及未来方向。
Front Pharmacol. 2025 Jun 12;16:1614325. doi: 10.3389/fphar.2025.1614325. eCollection 2025.
2
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.嵌合抗原受体细胞因子诱导的杀伤细胞（CAR-CIK）与嵌合抗原受体T细胞（CAR-T）对比：将新型细胞因子诱导的杀伤细胞作为erbB2阳性横纹肌肉瘤实体瘤免疫疗法的基准研究
Front Immunol. 2025 Feb 3;16:1485817. doi: 10.3389/fimmu.2025.1485817. eCollection 2025.
3

本文引用的文献

1
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.现货即用型 Vδ1 γδ T 细胞经 GPC-3 特异性嵌合抗原受体（CAR）和可溶性 IL-15 修饰后，显示出针对肝细胞癌的强大抗肿瘤疗效。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003441.
2
Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare.尽管存在安全恐慌，现成的基因编辑嵌合抗原受体T细胞（CAR-T细胞）仍在向前推进。
Nat Biotechnol. 2022 Jan;40(1):5-8. doi: 10.1038/d41587-021-00027-1.
3
NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
同种异体嵌合抗原受体 T 细胞治疗技术：是否兑现了承诺？
Cells. 2024 Jan 12;13(2):146. doi: 10.3390/cells13020146.
4
How can Cytokine-induced killer cells overcome CAR-T cell limits.细胞因子诱导的杀伤细胞如何克服 CAR-T 细胞的局限性。
Front Immunol. 2023 Aug 22;14:1229540. doi: 10.3389/fimmu.2023.1229540. eCollection 2023.
5
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.嵌合抗原受体 T 细胞疗法在头颈部癌症中的最新进展和未来展望。
Front Immunol. 2023 Jun 29;14:1213716. doi: 10.3389/fimmu.2023.1213716. eCollection 2023.
6
The Evolving Landscape of Potency Assays.效力测定的演进格局。
Adv Exp Med Biol. 2023;1420:165-189. doi: 10.1007/978-3-031-30040-0_11.
7
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.实体瘤过继细胞免疫治疗：除 CAR-T 以外的方法
Mol Cancer. 2023 Feb 7;22(1):28. doi: 10.1186/s12943-023-01735-9.
NKG2D 结合即可充分激活细胞因子诱导的杀伤细胞，而 2B4 仅提供有限的共激活作用。
Front Immunol. 2021 Oct 7;12:731767. doi: 10.3389/fimmu.2021.731767. eCollection 2021.
4
CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?B细胞淋巴增殖性疾病干细胞移植后的嵌合抗原受体T细胞疗法：它们真的是自体还是同种异体细胞疗法？
Cancers (Basel). 2021 Sep 17;13(18):4664. doi: 10.3390/cancers13184664.
5
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.基因编辑的、供体来源的同种异体抗 CD19 嵌合抗原受体 T 细胞治疗儿童和成人 B 细胞急性淋巴细胞白血病：两项 1 期研究结果。
Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5.
6
ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.工程化 ERBB2-CAR 细胞因子诱导的杀伤细胞对高危横纹肌肉瘤表现出 CAR 介导的和固有免疫双重作用。
Front Immunol. 2020 Oct 19;11:581468. doi: 10.3389/fimmu.2020.581468. eCollection 2020.
7
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.抗 GD2 CAR-NKT 细胞治疗复发或难治性神经母细胞瘤的初步临床研究
Nat Med. 2020 Nov;26(11):1686-1690. doi: 10.1038/s41591-020-1074-2. Epub 2020 Oct 12.
8
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.CSPG4 特异性 CAR.CIK 淋巴细胞治疗多种软组织肉瘤的新型疗法。
Clin Cancer Res. 2020 Dec 1;26(23):6321-6334. doi: 10.1158/1078-0432.CCR-20-0357. Epub 2020 Sep 8.
9
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.经基因编辑的 CAR T 细胞睡眠美人实现抗白血病活性而无严重毒性。
J Clin Invest. 2020 Nov 2;130(11):6021-6033. doi: 10.1172/JCI138473.
10
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.γδ CAR-T 细胞对白血病表现出 CAR 导向的和独立的活性。
Front Immunol. 2020 Jul 2;11:1347. doi: 10.3389/fimmu.2020.01347. eCollection 2020.